Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Oncolytics Biotech Inc. was founded in Calgary in 1998 in response to discoveries made on the oncolytic potential of reovirus made at the University of Calgary during the 1990s. In June 2000, it began trading on the Toronto Stock Exchange (TSX). On October 5, 2001, it was listed on the Nasdaq. More information...
According to PR-model, oncolyticsbiotech.com is ranked 1,492,947th in multilingual Wikipedia, in particular this website is ranked 831,912th in English Wikipedia.
The website is placed before volavola.org and after arpegediamonds.com in the BestRef global ranking of the most important sources of Wikipedia.
